- Home
- ARGX vs GEHC Comparison
ARGX vs GEHC Comparison
Compare ARGX & GEHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- GEHC
- Stock Information
- Founded
- ARGX 2008
- GEHC 1892
- Country
- ARGX Netherlands
- GEHC United States
- Employees
- ARGX N/A
- GEHC N/A
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- GEHC Computer Software: Prepackaged Software
- Sector
- ARGX Health Care
- GEHC Technology
- Exchange
- ARGX Nasdaq
- GEHC Nasdaq
- Market Cap
- ARGX 35.2B
- GEHC 40.4B
- IPO Year
- ARGX 2017
- GEHC N/A
- Fundamental
- Price
- ARGX $589.51
- GEHC $82.26
- Analyst Decision
- ARGX Strong Buy
- GEHC Buy
- Analyst Count
- ARGX 21
- GEHC 14
- Target Price
- ARGX $619.79
- GEHC $94.36
- AVG Volume (30 Days)
- ARGX 302.1K
- GEHC 3.5M
- Earning Date
- ARGX 10-31-2024
- GEHC 10-30-2024
- Dividend Yield
- ARGX N/A
- GEHC 0.14%
- EPS Growth
- ARGX N/A
- GEHC 8.27
- EPS
- ARGX N/A
- GEHC 3.65
- Revenue
- ARGX $1,908,659,000.00
- GEHC $19,559,000,000.00
- Revenue This Year
- ARGX $61.99
- GEHC $2.77
- Revenue Next Year
- ARGX $42.48
- GEHC $4.14
- P/E Ratio
- ARGX N/A
- GEHC $23.24
- Revenue Growth
- ARGX 85.56
- GEHC 1.43
- 52 Week Low
- ARGX $327.73
- GEHC $66.39
- 52 Week High
- ARGX $611.22
- GEHC $94.55
- Technical
- Relative Strength Index (RSI)
- ARGX 56.12
- GEHC 44.48
- Support Level
- ARGX $558.15
- GEHC $81.71
- Resistance Level
- ARGX $592.29
- GEHC $85.29
- Average True Range (ATR)
- ARGX 12.42
- GEHC 2.07
- MACD
- ARGX -2.11
- GEHC -0.10
- Stochastic Oscillator
- ARGX 56.76
- GEHC 37.38
About ARGX argenx SE
Argenx is a Dutch company focused on using its antibody engineering technology to treat rare autoimmune diseases. Vyvgart (efgartigimod) was initially approved in the US in December 2021 as a treatment for generalized myasthenia gravis, followed by approvals in Europe and Japan in 2022.
About GEHC GE HealthCare Technologies Inc.
GE HealthCare Technologies is a leading medical technology firm with leading market share in imaging and ultrasound equipment. The company reports four major segments: imaging (54% of revenue), ultrasound (18%), patient care solutions (16%), and pharmaceutical diagnostics (12%). The company's sales are geographically diverse, with the United States, EMEA, China, and the rest of the world accounting for 44%, 26%, 14%, and 16% respectively. We estimate approximately half of its revenue is recurring, which consists of servicing (33% of revenue), pharmaceutical diagnostics (12%), and digital solutions (6%).